April 06, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Omidria commercially available in US
Omidria is now commercially available in the United States, Omeros announced in a press release.
Omidria (1% phenylephrine and 0.3% ketorolac injection) is approved by the FDA for intraocular administration during cataract or IOL replacement surgery to prevent intraoperative miosis and reduce postoperative ocular pain.
The launch follows the successful completion of a 2-month controlled launch in which Omidria was available to a small number of ophthalmic surgeons for any necessary refinements in distribution, reimbursement and other commercial processes, the release said.
As of Jan. 1, CMS granted Omidria transitional pass-through status, which will remain in effect until Dec. 31, 2017.